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Abstract
Background: To investigate the influence of water intake and dose timing on the pharmacokinetic
and pharmacodynamic parameters of an oral formulation of salmon calcitonin (sCT).
Methods: The study was a randomized, partially-blind, placebo-controlled, single dose,
exploratory crossover phase I study. 56 healthy postmenopausal women were randomly assigned
to receive five treatments. The treatments comprised a combination of study medication (SMC021
(0.8 mg sCT + 200 mg 5-CNAC), SMC021 placebo, or 200 IU Miacalcic® NS nasal spray), water
volume given with the tablet (50 or 200 ml water), and time between dosing and meal (10, 30, or
60 minutes pre-meal). Plasma sCT levels and changes in the bone resorption (C-terminal
telopeptide of collagen type I) was investigated. Trial regristration
Results: Oral delivery of 0.8 mg of sCT with 50 ml of water compared to that with 200 ml water
resulted in a two-fold increase in maximum concentration (Cmax and AUC0–4) of plasma sCT but
comparable time to reach maximum concentration (Tmax). The sCT AUC0–4 with 50 ml of water
was 4-fold higher than that obtained with nasal calcitonin. The increased absorption of sCT resulted
in increased efficacy demonstrated by AUC of the relative change of serum CTX-I measured in the
6 hours post dosing.
Conclusion: 0.8 mg sCT with 50 ml of water taken 30 and 60 minutes prior to meal time resulted
in optimal pharmacodynamic and pharmacokinetic parameters. The data suggest that this novel oral
formulation may have improved absorption and reduction of bone resorption compared to that of
the nasal form.
Background
Calcitonin is a natural peptide hormone produced by
parafollicular cells (C-cells) in the thyroid gland [1,2],
which is secreted in response to excess calcium in the
serum [3]. Calcitonin was discovered more than 40 years
ago [4,5], and possesses potent anti-resorptive effects. Cal-
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clasts which result in a transient reversible inhibition of
bone resorption [6].
Calcitonin (CT) is approved for the treatment of oste-
oporosis and other diseases involving accelerated bone
turnover [6,7]. Calcitonin treatment has until now been
limited to either subcutaneous or intranasal administra-
tion, that occasionally is hampered by administration dif-
ficulties and local irritation [6]. Some subjects are
reluctant to administer drugs intranasal or parenteral lim-
iting the potential treatment population. An oral form of
calcitonin may improve subject acceptance and facilitate
improved subject compliance by providing a more accept-
able, alternative delivery route for peptide therapy [6].
Thus, an increasing number of investigations have
focused on formulating calcitonin to provide a novel oral
formulation that includes but not are limited to [6-18].
Oral drug delivery of small peptides is hampered by an
array of obstacles [19,20], including but not limited to
degradation by proteolytic enzymes in the digestive tract
and secondary intestinal uptake [19-21]. These difficulties
are best illustrated by the complete lack of peptides in oral
formulations approved by the FDA.
Due to the short half-life of calcitonin in serum several
attempts have been applied to increase plasma concentra-
tions. One very recent approach of oral calcitonin formu-
lation is the use of the Eligen technology [6]. This carrier
[7,22] interacts with the drug molecule to create an insol-
uble entity at low pH which later dissolves and facilitates
intestinal uptake, by enhancing peptide transport over the
non-polar biological membrane [22]. This has been dem-
onstrated to result in clinical efficacy [6,7].
Even in the face of already documented clinical efficacy
with this formulation [6,7], plasma concentrations of sCT
may be further optimized through pushing of gastric emp-
tying that would result in rapid transit of calcitonin
through the gastrointestinal tract [23]. This may partly cir-
cumvent calcitonin degradation by the vast array of
endopeptidases and other enzymes in the gastric tract
optimally functioning at low pH [19,20,23]. Several tech-
niques have been applied which prolong or shorten the
retention in the gastric tract, with more or less success
[19,20,24,25], in which the effect of water remains to be
carefully investigated in particular with special emphasis
on peptide uptake.
The primary objective of the current study was to investi-
gate the effects of two volumes of water used to take a sin-
gle SMC021 tablet and the effect of three different post-
dose meal timings on the pharmacokinetic (PK) and phar-
macodynamic (PD) profile of 0.8 mg sCT, as assessed by
Cmax and AUC0–4 of sCT and bone resorption by CTX-I.
Additionally the PK and PD profiles of intranasally
administered sCT (Miacalcic® 200 IU NS) were evaluated
for comparison in a small number of subjects; this treat-
ment was not blinded and therefore comparisons may be
affected by blinding bias.
Methods
Drug substance
SMC021 is an oral formulation of salmon calcitonin. It
consists of the peptide hormone and 5-CNAC, {8-(N-2-
hydroxy-5-chloro-benzoyl)-amino-caprylic acid)} a uni-
molecular enhancer of gastrointestinal peptide absorp-
tion, developed by Emisphere Technology, Inc. and
licensed to Novartis. The moiety was designed to deliver
peptides orally without significant enzymatic hydrolysis
or alteration of the biological characteristics of the pep-
tide. When 5-CNAC is administered orally in combina-
tion with salmon calcitonin (sCT), gastrointestinal
absorption of the sCT is markedly enhanced in rodents
and monkeys and humans.
Study design
The study was a randomized, partially-blind, placebo-
controlled, single dose, exploratory crossover study to
assess the PK and PD of 0.8 mg SMC021 in healthy post-
menopausal women when taken in the morning with dif-
ferent volumes of water (50 or 200 ml) and at different
times before a meal (10, 30, or 60 minutes). Subjects were
blinded to treatment with SMC021 and placebo, but were
not blinded to water volume intake and pre-meal dosing
time. The PK and PD profiles of Miacalcic® 200 IU NS were
additionally assessed in an open-label manner in a small
subset of subjects.
Females fulfilling the inclusion criteria of being generally
healthy ambulatory female volunteers, aged between 40–
70 years and having passed a natural or surgically-induced
menopause at least 5 years before entering the study and
being without diseases or medications known to affect
bone metabolism were allowed to participate. The study
was of a 5-period, 10-treatment, 56-sequence crossover
design. Subjects were randomly allocated to a sequence.
The study contained 10 possible treatments, comprising a
combination of study medication of SMC021, placebo,
and Miacalcic® NS), water volume given with the tablet
(50/200 ml water, and dosing time to meal (10, 30 or 60
minutes pre-meal) as outlined in Table 1. To reduce the
burden of treatment to the subjects, an incomplete cross-
over design was used. All subjects received five of these
treatments, according to pre-defined sequences, with a
minimum of a 3 day wash-out period between each dose.
No sequence included more than one dose of placebo,
and no sequence included the same treatment twice. The
subjects were blinded to treatment with SMC021 and pla-Page 2 of 10
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addition, no blinding was used for Miacalcic® 200 IU NS.
Placebo treatment was equally distributed across the dif-
ferent meal timings to balance the cross-over design.
After an overnight fasting period for at least 10 hours, the
subjects received the study medication at 08:00. For sub-
jects receiving either SMC021 or matching placebo, either
50 or 200 ml of water was given with the tablet, depend-
ing on the instructions provided for the specific dose in
the treatment sequence. For subjects receiving Miacalcic®
NS, no water was given with the dose. Except for the fluid
given at the time of drug intake and the drink given as part
of the standard breakfast, no fluid intake was allowed
from 1 hr before until 2 hrs after dosing. Otherwise, sub-
jects had a fluid intake of at least 200 ml every 4 hours,
starting from the time of dosing, in addition to fluid taken
with meals and medication. Apart from the breakfast
meal, no other food was consumed during the time inter-
val of blood sample collections.
For the evaluation of the pharmacokinetics and pharma-
codynamics, blood samples were collected immediately
prior to dosing (time 0 minutes), and at the intervals of 5,
10, 15, 30, 45 minutes, 1, 1 1/2, 2, 2 1/2, 3, 4, 5, and 6
hours after dosing. Plasma and serum samples were stored
at -20°C until analysis.
The concentration of plasma sCT was measured by as
chemiluminescence-based assay that previously have
been described [7]. Values measured below the lower
limit of quantification of 2.5 pg/ml was assigned the value
of 2.5 pg/ml. The assay was of the two-site immunometric
type, employing two antibodies, one biotinylated and the
other acridium labeled. Specificity has been tested against
synthetic fragments of sCT and against human as well as
eel calcitonin and negligible interaction has been found
over the range of standard curve. The lower limit of quan-
tification (LLOQ) was 2.5 pg/mL. The quality control
(QC) samples, ranging from 2.5 pg/mL to 700 pg/mL,
were prepared daily and measured in 3 to 5 replicates. The
overall accuracy and precision (CV) of QC samples, meas-
ured on 11 different days was 101.3% and 10.1% for 2.5
pg/mL concentration and 94.3% and 6.0% for 700 pg/mL
concentration, respectively.
The Serum CTX-I test is a sandwich enzyme enzyme-
linked immunosorbent assay (ELISA) employing two
monoclonal antibodies both recognizing the C-telopep-
tide of the α1-chain in type I collagen [26]. The mono-
clonal antibodies, i.e. MAb F1103 and MAb F12,
recognize the eight amino acid sequence EKAHD-β-GGR,
where D-β-G denotes an isomerised bond between aspar-
tate and glycine, and both antibodies require the presence
of a free C-terminal arginine for binding. Cathepsin K,
secreted by the osteoclast, is responsible for the proteo-
lytic cleavage exposing the free C-terminal arginine [27].
The sandwich construction assures that only cross-linked
di-peptides, i.e. EKAHD-β-GGR × EKAHD-β-GGR, are
measured by the Serum CTX-I ELISA. The measuring range
is 0.020–3.380 ng/ml, and in this range the intra- and
interassay coefficient of variation is <3.0 and <10.9%,
respectively, and the dilution recovery 103%. The refer-
ence range (mean (95% confidence interval)) for post-
menopausal and premenopausal women as well as men is
0.439 ng/ml (0.142 – 1.351 ng/ml), 0.287 ng/ml (0.112
– 0.738 ng/ml), and 0.294 ng/ml (0.115 – 0.748 ng/ml),
respectively, according to the manufacturer (Immunodi-
agnostic Systems Nordic, Herlev, Denmark) [26].
The study was conducted in accordance with Helsinki
Declaration II, and approved by local Ethical Committees
(ClinicalTrails.gov NCT00395395). Written informed
consent was obtained from all participants. A copy of the
written-consent form is on file, and is available for the edi-
tor-in-chief of this journal for review.
Table 1: Treatments and Dosing Regimens
Treatment Number Study medication Water volume Dosing time pre-meal
1 n = 40 SMC021 0.8 mg 50 ml 10 min
2 n = 40 SMC021 0.8 mg 50 ml 30 min
3 n = 40 SMC021 0.8 mg 50 ml 60 min
4 n = 40 SMC021 0.8 mg 200 ml 10 min
5 n = 40 SMC021 0.8 mg 200 ml 30 min
6 n = 40 SMC021 0.8 mg 200 ml 60 min
7 n = 10 Placebo 200 ml 10 min
8 n = 10 Placebo 200 ml 30 min
9 n = 10 Placebo 200 ml 60 min
10 n = 10 Miacalcic®200 IU NS N/A 60 minPage 3 of 10
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The primary objective was to compare the effect on the PK
profile of 0.8 mg sCT, as measured by Cmax and AUC0–4 hrs,
of the amount of water intake (50 ml or 200 ml) and the
effect of meal timing after the dosing (10, 30 or 60 min-
utes), a sample size of 56 subjects was determined to have
at least 83% power to reject the null hypothesis that the
absolute difference in the loge transformed sCT Cmax
value was above 0.693 using a 2-sided t-test at the 5% sig-
nificance level (transformed back to the original scale, the
null hypothesis corresponds to a ratio below 0.5 but
greater than 2). For the calculation, the mean square error
of the loge transformed sCT Cmax was estimated to be 1.0
and the expected ratio between the means was assumed to
be 0.95.
The trapezoidal method was applied for calculation of
AUC of plasma sCT and of relative change in serum CTX-
I after dosing. The relative value of serum CTX-I in post-
dose samples was calculated as percentage of the individ-
ual pre-dose value within each treatment period. The
relative change of serum CTX-I was determined as 100%
minus the relative value of serum CTX-I. The AUC of
plasma sCT, and the time course data of plasma sCT, and
serum CTX-I were logarithmically transformed to obtain
normality and symmetry of variances. Comparison
between treatments of Cmax and AUC of plasma sCT, and
AUC of relative change in serum CTX-I was performed
using a linear mixed effect model with the variable as the
response variable, and treatment (1, 2, 3, 4, 5, 6, and 10)
and period (1, 2, 3, 4 and 5) as fixed effects, and subject
as a random effect. A difference was considered significant
if p-value was less than 5%. No adjustments for multiplic-
ity were performed. The statistical calculations were per-
formed using the SAS software package (release 9.1, SAS
Institute Inc., Cary, NC, USA).
Results
The demographic characteristics of age, height, weight,
and BMI of the study participants are given in Table 2. The
subjects were aged between 56 and 70 years. All subjects
attended all 5 study periods.
The effect of water volume and time between dosing and
a subsequent meal on the absorption of sCT is shown in
Figure 1. The sCT appeared rapidly in plasma reaching
maximum concentrations approximately 15 minutes after
drug intake with minimal if any effect of water and meal
time on Tmax (Table 3). However, the level of the maxi-
mum concentration, Cmax, and the AUC of plasma sCT in
the period between dosing and 4 hours post-dose, was
dependent on the amount of water intake and timing of
meal. A two- to three fold higher absorption was attained
with the smaller amount of water of 50 ml as compared
with 200 ml (Figure 2) and Table 3, e.g. in the women
who fasted for 1 hour subsequent to dosing, the AUC0–4
hrs of sCT was 74.4 (pg/ml × hrs) when SMC021 was taken
with 50 ml of water and 33.6 (pg/ml × hrs) when taken
with 200 ml of water. The effect of water volume was sta-
tistically highly significant irrespective of post-meal tim-
ing (10, 30 and 60 minutes post-meal time: p < 0.001).
The AUC0–4 hrs of nasal calcitonin was 16.4 pg/ml × hrs,
lower than those observed with administration of 0.8 mg
of oral sCT, although the comparison is based on a
smaller number of observations There was increased
absorption with delayed intake of meal, especially for the
groups with intake of 50 ml of water, but the effect of tim-
ing of meal was far less pronounced than that of water.
The delayed intake of water significantly increased sCT
when comparing 10 and 60 minutes, and was borderline
significant at 30 minutes compared to that of 10 minutes.
Following the absorption phase, sCT was rapidly elimi-
nated from the circulation with an elimination half-life
T1/2 between 11 and 20 minutes comparable between all
groups (data not shown).
In accordance with the absorption of sCT, the water vol-
ume and time of meal post-dosing revealed a similar phar-
macodynamic effect on bone resorption, measured by
concentration of serum CTX-I over the 6 hours post-dose
(Figure 3 and 4). Overall, dosing with SMC021 resulted in
a significant suppression of serum CTX virtually reaching
the same level of nadir 3 to 4 hours post-dose irrespective
of water volume and time of meal post-dosing (Figure 3).
However, the remission to baseline started earlier in sub-
jects who took the medication with 200 ml of water as
compared to that with 50 ml. In similar context, return to
baseline values occurs earlier in subjects who had intake
of meal 10 minutes after dosing as compared to those hav-
ing meal 30 and 60 minutes after dosing. Taken together,
and as presented in Figure 4, the largest treatment effect
measured as the AUC of change in relative values of serum
CTX-I during the 6 hours post-dose was achieved for the
oral dose of 0.8 mg taken with 50 ml of water, 30 or 60
minutes before meal intake. The placebo-adjusted treat-
ment effect of the dose given 60 minutes prior to meal was
-171 (% × hrs) and -202 (% × hrs) for 0.8 mg SMC021
taken with 200 ml and 50 ml of water, respectively, and -
114 (% × hrs) in the subjects receiving nasal calcitonin.
Table 2: Characteristics of study population (n = 56)
Mean (SD) Range
Age (Yrs) 64.2 (3.5) 56 – 70
Height (m) 163.9 (5.9) 151 – 177
Weight (kg) 68.4 (7.8) 53.4 – 87.5
BMI (kg/m2) 25.5 (2.8) 20.1 – 30.1Page 4 of 10
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Time course of plasma sCT 2 hours following one single dose of 0.8 mg with either 50 or 200 ml of water compared of that of Nasal sCT, as indicated in the legendF gure 1
Time course of plasma sCT 2 hours following one single dose of 0.8 mg with either 50 or 200 ml of water com-
pared of that of Nasal sCT, as indicated in the legend. Values given are geometric mean ± 1 SEM.
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Oral drug delivery of small peptides is hampered by an
array of obstacles that are best illustrated by the complete
lack of peptides in oral formulations approved by the
FDA. We have investigated the effect of water and meal
time on the absorption of a single tablet of 0.8 mg of
salmon calcitonin given orally by pharmacokinetic and
pharmacodynamic parameters and compared them to
that of the nasal spray of calcitonin given in a dose of 200
IU. These data are the first to demonstrate oral delivery of
a small peptide in which optimization of drug intake
parameters including amount of water intake can aug-
ment bioavailability and subsequently improve PD effect
over 6 hours. The currently presented results are especially
important in determining the optimal oral delivery of cal-
citonin, and they may be of use in development of other
peptides to be formulated for oral administration.
An array of attempts have been made to formulate calci-
tonin for oral administration [9,10,12-
AUC of plasma sCT in the 2 hours following one single dose of 0.8 mg with either 50 or 200 ml of water compared of that of Nasal sCT, as indicated in the legendFigure 2
AUC of plasma sCT in the 2 hours following one single dose of 0.8 mg with either 50 or 200 ml of water com-
pared of that of Nasal sCT, as indicated in the legend. Values given are geometric mean ± 1 SEM.
Table 3: Pharmacokinetic profile
Study medication Water Volume Dose pre-meal AUC0–4 pg/ml × hrs Cmax pg/ml Tmax minutes
SMC021 50 ml 10 min 52.2 (46.0–59.4) 103 (89–118) 15 (10–23)
SMC021 50 ml 30 min 68.9 (60.2–78.9) 125 (110–144) 15 (15–30)
SMC021 50 ml 60 min 74.4 (64.0–86.5) 145 (125–168) 15 (15–30)
SMC021 200 ml 10 min 27.4 (25.2–29.7) 52 (45–59) 15 (10–15)
SMC021 200 ml 30 min 32.9 (29.1–37.3) 56 (48–67) 15 (15–30)
SMC021 200 ml 60 min 33.6 (29.5–38.1) 49 (42–58) 15 (12.5–30)
Miacalcic N/A 60 min 16.4 (13.8–19.4) 11.4 (8.3–15.5) 15 (10–15)
AUC0–4 and Cmax is given as geometric mean (mean ± 1 sem), and Tmax as median (25–75 percentile)Page 6 of 10
(page number not for citation purposes)
BMC Clinical Pharmacology 2008, 8:5 http://www.biomedcentral.com/1472-6904/8/5
Page 7 of 10
(page number not for citation purposes)
Time course of absolute level of serum CTX-I in the 6 hours following one single dose of 0.8 mg with either 50 or 200 ml of wat r compared of that of Nasal sCT, as indicated in the legendF gu e 3
Time course of absolute level of serum CTX-I in the 6 hours following one single dose of 0.8 mg with either 50 
or 200 ml of water compared of that of Nasal sCT, as indicated in the legend. Values given are geometric mean ± 1 
SEM.
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already has been proven to be useful clinically [6,7]. Even
in the face of already proven clinical pharmacodynamic
effects [6,7], administration of this novel formulation
may possibly be optimized further to enhance uptake and
thereby improve clinical effect.
The current study clearly suggests that drug uptake of
SMC021 is influenced by the amount of water given with
the tablet. A water volume of 50 ml resulted in a two- to
three-fold higher absorption of sCT in comparison with a
volume of 200 ml of water. This doubling of absorption
was seen irrespective of the timing of meal after dosing,
i.e. meal given 10, 30, and 60 minutes post dosing, sug-
gesting an impact of water intake on digestion and
absorption. Secondarily, this resulted in improved effi-
cacy, measured by the biochemical marker of bone resorp-
tion, serum CTX-I. These data are the first to demonstrate
that water intake has an important effect on oral peptide
uptake with the Eligen technology, improving bioavaila-
bility as much as 400%, and even more if placebo cor-
rected. This finding may be extended to other
formulations.
Previous studies have indicated that the bioavailability of
some drug substances is heavily influenced by meal time
[29-31] compared to that of fasting state [32-34]. The
effect of meal timing on the oral delivery of small pro-
teins/peptides has been investigated less than that of
small molecules. The present study investigated the effect
of two water volumes (50 mL and 200 mL) and meal
intake (10, 30, and 60 minutes) after drug dosing to deter-
mine optimal dosing conditions. Dosing 60 minutes prior
to meal time with 50 ml of water was significantly better
compared to 10 minutes. This was borderline significant
for 30 minutes. The results of the study are in alignment
with previous studies, documenting the strong suppres-
sion of drug uptake when food is taken concomitantly
[35,36]. However these interactions are highly drug-spe-
cific, which hampers the general conclusions drawn, as
lipophilic, hydrophilic and proteins all have different
characteristics.
Biochemical markers of bone resorption such as serum
CTX-I have on previous occasions been demonstrated to
be independent predictors of fracture risk and predictive
of drug efficacy [27,37]. Serum CTX-I, which is an osteo-
clast specific generated collagen type I fragment [38], was
significantly inhibited by oral sCT treatment to a greater
extent than by the nasal formulation over 6 hours. This
may be interpreted as a potential better efficacy. Thus,
these data suggest the possibility of efficacy superior to
that of the nasal spray observed in previously clinical trials
[39].
AUC of relative change in serum CTX-I in the 6 hours following one single dose of 0.8 mg with either 50 or 200 ml of water compared of that of Nasal sCTFigure 4
AUC of relative change in serum CTX-I in the 6 hours following one single dose of 0.8 mg with either 50 or 200 
ml of water compared of that of Nasal sCT. Values given are geometric mean ± 1 SEM.Page 8 of 10
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[35,40], most of which is linked to a post-prandial
decrease [27,36]. In the current study, this effect was
clearly observed after the placebo treatment when the
decrease in CTX-I started at meal time.
Conclusion
In conclusion, these data suggest that SMC021 given with
50 ml of water prior to meal time results in greater sCT
bioavailability than when given with 200 ml of water, and
that timing the dose 60 minutes pre-meal results in greater
sCT bioavailability than 10 minutes pre-meal. Also, the
sCT bioavailability and CTX-I pharmacodynamic effect
appear to be greater compared to that of nasal calcitonin.
Further clinical studies are needed to evaluate the safety
and efficacy of SMC021 for the treatment of osteoporosis.
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